What's new?
10/07/2018

Paris, France, July 10th. 2018. Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.

ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.

ReCor Medical is an innovative medical device company that developed the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.

Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”

Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”

Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”

Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.

For more information, please contact:
SOFINNOVA PARTNERS
International: Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com
United States: Kate Barrette
Tel: +1 212 223 0561
e-mail: kbarrette@rooneyco.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management. For more information: www.sofinnova.fr

About ReCor Medical, Inc.
ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System’s intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a feasibility study of patients with resistant hypertension) and REQUIRE (a pivotal study of patients with resistant hypertension in Japan and Korea), and launch the RADIANCE II pivotal study (a study of patients with moderate hypertension) in the United States and Europe.
http://www.recormedical.com/

About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd.
Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.
http://www.otsuka.com/en/

Established in 2011, Otsuka Medical Devices Co., Ltd. is a fully-owned subsidiary of Otsuka Holdings and one of its core operating subsidiaries. Otsuka Medical Devices focuses on the development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment.
Otsuka Medical Devices conducts the REQUIRE trial for renal denervation in hypertensive patients (n=140), who are uncontrolled on 3 or more medications including a diuretic, in Japan and Korea through its subsidiary JIMRO Co., Ltd.
http://www.omd.otsuka.com/en/

12/09/2018

LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 11, 2018 — ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the closing of its previously announced underwritten public offering of 6,612,500 ordinary shares at a price to the public of $15.75 per share. The closing included the full exercise of the underwriters’ option to purchase 862,500 additional ordinary shares at the public offering price, less underwriting discounts and commissions. Gross proceeds from the offering totaled approximately $104.1 million, before deducting underwriting discounts and commissions and offering expenses.
Citigroup, Evercore ISI and RBC Capital Markets acted as joint bookrunners for the offering. H.C. Wainwright & Co. and Chardan acted as co-managers for the offering. Kempen & Co acted as the Company’s European financial advisor in relation to this offering.
A shelf registration statement relating to the offered ordinary shares was filed with the Securities and Exchange Commission (SEC) on October 2, 2015, which was declared effective on October 19, 2015. A prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; Evercore ISI, Attention: Equity Capital Markets, 55 East 52nd Street, 36th Floor, New York, NY 10055, or by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com; or RBC Capital Markets, LLC, Attention: Equity Syndicate, 200 Vesey Street, 8th Floor, New York, NY 10281, or by telephone at (877) 822-4089, or by email at equityprospectus@rbccm.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases such as Leber’s congenital amaurosis 10, dystrophic epidermolysis bullosa and cystic fibrosis. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
*Since 2012*

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to”, “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements about ProQR’s business and efforts to develop RNA medicines. These forward-looking statements involve risks and uncertainties, many of which are beyond ProQR’s control. Applicable risks also include those that are included in ProQR’s prospectus supplement and accompanying prospectus filed with the SEC for the offering, including the documents incorporated by reference therein, which include ProQR’s Annual Report on Form 20-F for the year ended December 31, 2017, and any subsequent SEC filings. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.

ProQR Therapeutics N.V.:
Smital Shah
Chief Financial Officer
T: +1 415 231 6431
ir@proqr.com

11/07/2018

– Dr. Henig adds leadership and development expertise in pulmonary disease, inhaled therapies, and orphan disease to the executive management team
– Breath Therapeutics is targeting Bronchiolitis Obliterans with their first molecule, a Phase 3 ready asset

Munich, Frankfurt, Boston, July 11, 2018 — Breath Therapeutics B.V. (Breath), a private company developing advanced drug-aerosol therapeutics in pulmonary orphan indications, announced today the appointment of Noreen Roth Henig, M.D. as Chief Medical Officer. Dr. Henig joins the executive management team and will lead Breath’s clinical development activities.
Dr. Henig brings to Breath more than 20 years of clinical and development leadership experience at emerging and leading biopharmaceutical companies, complemented by extensive medical experience in pulmonary and transplant medicine. Her expertise substantially strengthens BOSTON, the lead development program of inhaled L-CsA (Liposomal Cyclosporine A), for the treatment of Bronchiolitis Obliterans (BO), a lethal orphan respiratory disease. Breath’s pipeline of inhaled therapeutics is targeting severe respiratory diseases with high unmet medical need.
“Noreen´s background in advanced lung disease and lung transplant, her senior drug development expertise, and her strong strategic corporate thinking is an outstanding combination and perfectly complements the Breath management team”, said Dr. Jens Stegemann, Chief Executive Officer of Breath Therapeutics.

Noreen Henig stated: “I am looking forward to joining the Breath Therapeutics team and to growing the young company. This is a unique opportunity to develop a promising Phase 3 ready asset for a true unmet medical need”.

Prior to joining Breath, Dr. Henig was CMO of ProQR Therapeutics, where she oversaw all preclinical and clinical development of candidate molecules and was also responsible for patient safety, data transparency, medical ethics and governance. She successfully led the young biotech company through organic growth and was instrumental in raising a pre-IPO series and a successful NASDAQ IPO for the then preclinical stage company. Previously, Dr. Henig served as Senior Director, Global Medical Affairs, Respiratory and PAH of Gilead Sciences, where she designed and executed clinical trials, up to Phase 4. In particular, she provided medical support to two therapies indicated for severe pulmonary disease. Throughout her career, Dr. Henig has held several senior academic positions related to respiratory diseases and lung transplant at the California Pacific Medical Center and the Stanford University School of Medicine. She earned her M.D. with Distinction in Immunology from the Albert Einstein College of Medicine, c mpleted training in Internal Medicine at UCSF and Pulmonary and Critical Care Medicine at University of Washington, Seattle.

About Bronchiolitis Obliterans (BO)
Bronchiolitis Obliterans (BO) is a severe progressive orphan disease of the bronchioles of the lung that leads to death from respiratory failure. BO is the leading cause of loss of transplanted lungs.
Of more than 25 000 people currently living with a lung transplant, approximately half will die within the next five years, mainly related to BO. BO also occurs in patients following allogeneic hematopoietic stem cell transplant, autoimmune disease and some environmental exposures.

About Breath Therapeutics
Breath is a clinical stage biopharmaceutical company specializing in advanced and first-in-class inhalation therapies for severe respiratory diseases with high unmet medical need. For its clinical development, the Company is using new proprietary drug formulations optimized for inhaled administration with exclusively licensed, high performance nebulizers. Breath is focusing on integrated therapy solutions in the interaction between diagnostics, therapeutics and eHealth therapy monitoring.
Breath´s lead development program BOSTON is addressing the treatment of BO with a proprietary formulation of liposomal cyclosporine for inhalation. With proceeds from a USD 46 million Series
A financing by top-tier European investors Sofinnova, Gimv and Gilde Healthcare, the Company is currently initiating Phase 3 studies in the US and Europe. PARI Pharma, a worldwide leading nebulizer company, is a strategic development partner and licensor for the eFlow® nebulizer technology for Breath’s BOSTON program.
Breath Therapeutics is Germany and US based with offices in Frankfurt, Munich and Boston.
For more information, please visit www.breath-therapeutics.com

Contact:
Breath Therapeutics B.V.
Dr. Jens Stegemann, CEO
Email: contact@breath-therapeutics.com
Media inquiries:
MC Services AG
Dr. Claudia Gutjahr-Loeser, Managing Director
Tel. +49 89 210 228–0
Email: breath-therapeutics@mc-services.eu

10/07/2018

The CALYPSO program will receive 14 million euros to develop CorWave Neptune, a new type of cardiac support to improve the management of patients with severe heart failure, as part of the Program d’Investissements d’Avenir (PIA) operated by Bpifrance.

The CALYPSO Research and Development (R&D) program, with a total budget of 25 million euros over 4 years, will be partially financed with 14 million euros support from the Program d’Investissements d’Avenir (Future Investments Program), managed by the Secrétariat Général pour l’Investissement (General Secretariat for Investment – SGPI) and operated by Bpifrance.
A breakthrough technology addressing an important public health issue: chronic heart failure. The CALYPSO program aims to optimise and then clinically evaluate the CorWave Neptune device, an implantable cardiac support blood pump (Left Ventricular Assist Device or LVAD). Neptune features natural physiological response, designed to reduce the risk of complications associated to current LVADs and intended for patients suffering from severe heart failure. Heart failure is involved in one in ten deaths in France. This chronic disease can be fatal, with nearly half of patients dying within five years of diagnosis. The number of patients affected by heart failure increases as the population ages and becomes more sedentary.

Louis de Lillers, CEO of CorWave, leader of the CALYPSO project: ” We are very pleased to set up major partnerships with world-class university hospitals, thanks to the financial support of Bpifrance and the French Government. The CALYPSO program considerably increases the resources allocated to preclinical and clinical studies prior to the marketing of Neptune, a cardiac support pump that closely mimics the physiological flow of the native heart. This program will help CorWave convert its disruptive technology into a sustainable competitive advantage to establish itself, as a global leader in cardiac support, a market that already accounts for nearly $1 billion in annual sales.”
Professor Pascal Leprince, Head of Cardiac and Thoracic Surgery at the AP-HP Pitié-Salpêtrière Hospital and Professor at the Sorbonne University Faculty of Medicine: “With its breakthrough technology, CorWave is in principle capable of generating pulsatile flow, similar to that of the body’s normal physiology, reducing the serious complications associated with continuous flow pumps. Our teams, in collaboration with the IHU-ICAN research teams and the medical teams at CHU de Lille Hospital, look forward to conducting clinical trials with patients equipped with current and future LVAD technology.”

Professor Sophie Susen, Head of Haemostasis and Transfusion at the CHU de Lille hospital and Professor in the Faculty of Medicine at University of Lille: “We are thrilled to be participating in the development of the CorWave Neptune pump through our experimental models and our expertise in haemostasis. We hope to better understand and control the risk of bleeding involved in the operation of current rotary pumps. The collaboration with the AP-HP Pitié-Salpêtrière Hospital and LadHyX is an opportunity to create a cross-sectoral impetus in France that, in addition to supporting the development of CorWave, will advance the understanding of bleeding associated with circulatory assistance.”

The CALYPSO consortium is led by CorWave, the main project partner, and includes:
• CorWave, a French high-tech company that develops innovative implantable heart pumps using a disruptive technology, the wave membrane. This patented technology, inspired by nature, is capable of replicating a pulse and flow velocity similar to those of a healthy heart, thereby reducing the risk of complications associated with current pumps. Supported by renowned investors and the recipient of numerous awards for its pioneering technology, CorWave has been identified as a company with hyper-growth potential.
• AP-HP Pitié-Salpêtrière Hospital is one of the world’s top three heart transplant centres and a world-renowned cardiac support centre, and the leading LVAD implant centre in France.
• Lille University Hospital is a centre of excellence in the treatment of Willebrand disease and is world-renowned for its expertise in haemostasis, in particular the assessment of haemorrhagic risk in patients with implantable cardiac devices. This team was the first to describe the links between flow abnormalities and blood biology in a 2003 publication in the New England Journal of Medicine.

The consortium will also work with the French Institute of Cardiometabolism and Nutrition (IHU-ICAN), as part of the clinical studies conducted with teams from the AP-HP Pitié-Salpêtrière Hospital, and the INSERM research institute in conjunction with Lille University Hospital. It will also benefit from the expertise of eDevice, a company specialising in the development of telemedical solutions, and LadHyX, the hydrodynamics laboratory at the Ecole Polytechnique, which will provide support in the field of fluid biomechanics in cooperation with Lille University Hospital.

CorWave, the CALYPSO program leader, will coordinate all the R&D and clinical investigation activities for the project and is responsible for ensuring its successful execution. The CALYPSO program is designed to incorporate all the development stages of the Neptune cardiac assistance pump, as well as a scientific and clinical support, essential to ensure the device obtains CE marking. The improvement of the risk-benefit associated with LVADs via the optimisation of Neptune’s operating parameters during the program should make it possible to reduce complications and to be able to offer this effective therapy to a wider patient population.
The CALYPSO program will enable CorWave to maintain its technological lead and strengthen its clinical impact by greatly improving therapy and care for patients fitted with LVADs.

About CorWave
CorWave is a French company that develops innovative cardiac support devices. The CorWave technology stands out from other LVADs currently on the market due to its physiological design enabled by a unique undulating membrane. Among other things, it is able to mimic a pulse and produce blood flow velocity similar to that of a healthy heart. Eventually, CorWave’s membrane pump technology should reduce complications associated with current devices and improve the care of patients with heart failure, a market potentially worth several billion euros.
Founded in 2011 by the incubator MD Start and supported by well-known investors, including Bpifrance, Novo Seeds, Seventure, Sofinnova and Ysios, CorWave has received over €20 million of financing and employs more than fifty people.
Find out more: www.corwave.com

About Bpifrance
Bpifrance finances companies – at every stage of their development – through loans, guarantees and equity capital. Bpifrance supports them in their development projects and internationally. Bpifrance now offers a wide range of products to help them in their export business. The company also offers consulting, university, networking and acceleration programs for start-ups, SMEs and IT companies. Thanks to Bpifrance and its 48 regional offices, entrepreneurs benefit from a close, exclusive and efficient partner to help them face their challenges.
More information at: www.bpifrance.fr /presse.bpifrance.fr Follow us on Twitter: @Bpifrance – @BpifrancePresse

About AP-HP
The AP-HP is a university hospital centre and a major player in clinical research in France and Europe, as well as being renowned worldwide. Its 39 hospitals treat 10 million patients each year: on an emergency basis, during scheduled hospitalisations or at home. It provides a public health service open to all, 24 hours a day, which is both a duty and a source of pride. The AP-HP is the largest employer in the Greater Paris region: 95,000 people – doctors, researchers, paramedics, administrative staff and workers – work there.
Find out more: www.aphp.fr

About the Program d’Investissements d’Avenir (Future Investments Program)
With a budget of 57 billion euros, the Program d’Investissements d’Avenir (PIA), led by the General Secretariat for Investment (SGPI), was set up by the State to finance innovative and promising investments in France. Six national priorities have thus been identified to enable France to increase its growth and employment potential:
● higher education, research and training,
● the development of research and its spin-off to the world of business,
● sustainable development,
● industry and SMEs,
● the digital economy,
● health and biotechnology.
The third component of the PIA, the PIA3, is part of the General Investment Plan (GPI) laid out by the French prime minister on 25 September 2017.
To learn more about investments in the future: http://www.gouvernement.fr/secretariat-general-pour-linvestissement- sgpi
Twitter: @SGPI_avenir

About CHU de Lille Hospital
Lille University Hospital is one of the largest university hospitals in France, bringing together a community of more than 16,000 professionals whose multidisciplinary expertise in the fields of care, research and innovation is internationally recognised. Lille University Hospital is one of France’s leading university hospitals in terms of the quality of its research and its research is organised around six different fields: Cancer – Neurosciences – Inflammation, infection and immunity – Metabolic and cardiovascular diseases – Longevity – Prevention.

Press contacts:
CorWave
Florence Portejoie
FP2COM
+ 33 (0) 6 07 76 82 83
fportejoie@fp2com.fr

Bpifrance
Annelot Huijgen
+33 (0)1 41 79 94 48
annelot.huijgen@bpifrance.fr
Secrétariat Général pour l’Investissement (SGPI)
Vincent Deshayes
+33 06 98 60 55 31
Vincent.deshayes@pm.gouv.fr

10/07/2018

Paris, France, July 10th. 2018. Sofinnova Partners, a leading venture capital firm specialized in Life Sciences, today announced that Otsuka Holdings is acquiring its portfolio company ReCor Medical, a medical device company specialized in the treatment of hypertension. The terms of the acquisition are being withheld due to non-disclosure obligations.

ReCor Medical was created in 2009 by Sofinnova Partners, Mano Iyer – who was then entrepreneur-in-residence at Sofinnova Partners and now Chief Operating Officer of ReCor – and Professor Jacques Seguin, MD, who became a large private investor in ReCor. Prof. Seguin was previously founder and CEO of CoreValve, a past Sofinnova portfolio company and a leader in the transcatheter valve replacement space, which was sold to Medtronic. Sofinnova Partners was the sole venture capital investor in ReCor Medical and remained its largest shareholder until the sale to Otsuka.

ReCor Medical is an innovative medical device company that developed the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. ReCor recently announced positive results of its landmark RADIANCE-HTN SOLO hypertension study at EuroPCR 2018.

Antoine Papiernik, Managing Partner at Sofinnova Partners and ReCor Board Member, said: “ReCor perfectly illustrates our investment strategy: we worked hand-in-hand with Mano Iyer to create the business vision and plan for ReCor. We then founded and funded the company, and opened our network of experts, key opinion leaders and board members to help grow it. We brought trusted entrepreneurs Jay Watkins as Chairman and Andy Weiss as CEO to help guide and operate the company through to a corporate transaction to our partner Otsuka.”

Jay Watkins, Chairman of ReCor Medical said: “Sofinnova Partners remains one of few VCs willing to fund early-stage med-tech ventures targeting large and important new markets. The firm played a critical role throughout ReCor’s life, and has proven to be a reliable, value-added partner for the company. The field of renal denervation has been a complex one over the last few years with periods of euphoria and periods of doubt. Sofinnova Partners’ support remained constant throughout, helping to build a strong partnership with Otsuka and then navigate through the challenges to a very successful trade sale.”

Mano Iyer, Founder and COO of ReCor Medical added: “ReCor is a success story because Sofinnova Partners, consistent with its philosophy, saw the value of an opportunity which did not yet exist. It had the vision to create and fund the company, not only in the very beginning, but also during the critical early years. Despite the dramatic swings in the field, Sofinnova Partners’ confidence in me and in the management team was essential to keep us motivated when others lost hope. This great exit is therefore particularly sweet.”

Andrew M. Weiss, CEO of ReCor Medical adds: “I came to ReCor thanks to Antoine Papiernik’s introduction to the company. With his help, our team developed the partnership with Otsuka and was able to remain focused on value creation. The recent announcement of our positive RADIANCE-HTN SOLO study results and now the merger with Otsuka demonstrate that our teamwork with Sofinnova Partners was successful. We now have an opportunity to transform the treatment of hypertension and benefit millions of potential patients while providing a solid return for our investors. I look forward to continuing to work to make this technology a possible standard of care in hypertension treatment”.

For more information, please contact:
SOFINNOVA PARTNERS
International: Anne Rein
Tel: +33 6 03 35 92 05
e-mail: anne.rein@strategiesimage.com
United States: Kate Barrette
Tel: +1 212 223 0561
e-mail: kbarrette@rooneyco.com

About Sofinnova Partners
Sofinnova Partners is a leading European venture capital firm specialized in Life Sciences. Based in Paris, France, the firm brings together a team of professionals from all over Europe, the US and China. The firm focuses on paradigm shifting technologies alongside visionary entrepreneurs. Sofinnova Partners seeks to invest as a lead or cornerstone investor in seed, start-ups, corporate spin-offs and late stage companies. It has backed nearly 500 companies over more than 45 years, creating market leaders around the globe. Today, Sofinnova Partners has over €1.9 billion under management. For more information: www.sofinnova.fr

About ReCor Medical, Inc.
ReCor Medical is a medical device company that designs and manufactures the Paradise System, a proprietary ultrasound ablation system for renal denervation (RDN). RDN is a new potential therapeutic approach for the treatment of hypertension, one of the most prevalent medical conditions. The Paradise System is approved for sale in the EU and bears a CE mark, but is not approved for sale in the United States. The System’s intravascular catheters denervate renal nerves by combining the protection of water-based cooling of the renal artery with high intensity ultrasound energy for circumferential renal nerve ablation. The Paradise System has been studied in clinical trials of approximately 300 patients to date. Following the positive outcomes of the RADIANCE-HTN SOLO trial, ReCor will continue its evaluations of Paradise in RADIANCE-HTN TRIO (a feasibility study of patients with resistant hypertension) and REQUIRE (a pivotal study of patients with resistant hypertension in Japan and Korea), and launch the RADIANCE II pivotal study (a study of patients with moderate hypertension) in the United States and Europe.
http://www.recormedical.com/

About Otsuka Holdings Co., Ltd. and Otsuka Medical Devices Co., Ltd.
Otsuka Holdings Co., Ltd. is the holding company of the Otsuka group, a global healthcare group headquartered in Tokyo, Japan. With operations in pharmaceuticals, nutraceuticals, medical devices and other health-related businesses, the group generated worldwide sales of JPY1,240 billion in the fiscal year ended December 2017.
http://www.otsuka.com/en/

Established in 2011, Otsuka Medical Devices Co., Ltd. is a fully-owned subsidiary of Otsuka Holdings and one of its core operating subsidiaries. Otsuka Medical Devices focuses on the development and commercialization of endovascular devices that provide new therapeutic options in areas where patient needs cannot be met through pharmaceutical or other conventional treatment.
Otsuka Medical Devices conducts the REQUIRE trial for renal denervation in hypertensive patients (n=140), who are uncontrolled on 3 or more medications including a diuretic, in Japan and Korea through its subsidiary JIMRO Co., Ltd.
http://www.omd.otsuka.com/en/

03/07/2018

Cambridge, UK, 2 July 2018 – Crescendo Biologics Ltd (Crescendo), the drug developer of novel, targeted T-cell engaging therapeutics, today announces that Igor Matushansky, MD, PhD, has been appointed as Non-Executive Director of the Company with immediate effect.

Igor is currently Chief Medical Officer and Global Head of R&D at Hookipa Biotech AG (Hookipa), a clinical stage immuno-therapy biotech. Prior to Hookipa, Igor was the Global Head of Translational Development for Oncology at Daiichi Sankyo, where he focused on early oncology therapeutic programmes, strategy and development. Prior to that, Igor was at Novartis where he was the Global Head for Clinical and Scientific Development at its Gene & Cell Therapy Unit as well as a Global Clinical Program Lead within Novartis’ Oncology Translational Medicine Unit.
Before moving into the pharmaceutical industry in 2010, Igor was a Professor at the Columbia University Medical Center where he ran an independent laboratory and clinic focusing on the molecular biology, translational opportunities and clinical trials in sarcomas. Currently Igor is an Adjunct Professor of Medical Oncology at Columbia University.
He previously received his MD and PhD in Molecular Biology from the Albert Einstein College of Medicine. He performed his Internal Medicine residency at New York Presbyterian Hospital – Weill Cornell Medical Center and then completed a fellowship in Medical Oncology and a post-doctoral research fellowship in Cancer Biology at the Memorial Sloan Kettering Cancer Center.
Kevin Johnson, Chairman of the Board of Directors at Crescendo Biologics, said:
“Igor has led oncology R&D units at large pharma companies, Daiichi Sankyo and Novartis, as well as at biotech, Hookipa. He has unique immuno-oncology expertise which makes him the ideal addition to the Board. With this appointment, Crescendo has further strengthened its expertise in clinical development and its position at the forefront of next generation immuno-oncology therapy companies.”
Igor Matushansky, Non-Executive Director, also commented:
“Crescendo is developing a very exciting and novel class of targeted biologics that hold real promise in the treatment of solid tumours. These multi-specific, minimally-sized Humabody® products are highly differentiated from conventional antibodies and have the potential to revolutionise cancer medicine. Crescendo’s recent $70 million Series B enables it to drive its lead programmes into the clinic and I look forward to being part of this real success story.”

For more information, please contact:
Crescendo Biologics Dr Peter Pack, CEO
+ 44 (0)1223 497140
info@crescendobiologics.com

For Media:
Instinctif Partners for Crescendo Biologics
Deborah Bell, Dr Christelle Kerouedan, Melanie Toyne-Sewell
+ 44 (0)20 7457 2020
crescendo@instinctif.com

About Crescendo Biologics
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody® therapeutics in oncology with a focus on innovative targeted T-cell approaches.
Leading its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity. This highly modular format can be re-configured to create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting any of a range of alternative tumour-specific markers.
The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel biology and superior bio-distribution. This results in larger therapeutic windows compared to conventional IgG approaches.
Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships, including multi-functional immuno-oncology modulators and Humabody® drug conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be applied across a range of non-cancer indications.
Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, Andera Partners, IP Group, Takeda Ventures, Quan Capital, Astellas and EMBL ventures.
For more information, please visit the website: www.crescendobiologics.com.

02/07/2018

Green Biologics Announces Launch of First Bio-Based Acetone Nail Polish Remover
To be introduced in Sally Beauty Stores Nationwide

Little Falls, MN (June 25, 2018): Green Biologics, Inc., announced the commercial launch of the world’s first bio-based acetone nail polish remover. Sally Beauty is the first retailer to carry the sustainably-produced nail polish remover and is carrying it in over 3,000 stores nationwide. The product, which is branded under the Sally Beauty “Beauty Secrets” line, is a collaboration of Green Biologics and Marianna Industries, a leading developer and manufacturer of beauty products.
“We are very excited to introduce the first plant-derived acetone nail polish remover,” said David Anderson, Global Vice President of Marketing, Green Biologics. “Consumers are more particular than ever about the ingredients in their household and personal care products and are demanding more eco-friendly formulations. This nail polish remover was created to directly address this demand with a formulation that works equally as good as traditional acetone remover, meaning consumers don’t need to sacrifice performance for natural ingredients.”
The key component of this plant-derived nail polish remover is 100% renewable acetone, a bio-based chemical produced via a patented fermentation process at Green Biologics’ plant in Little Falls, MN. United States grown corn is the primary feedstock. Although sustainably-sourced, this renewable acetone is a high-performance ingredient, equally effective to conventional acetone-based removers.
Green Biologics’ acetone nail polish remover is 100% certified as USDA BioPreferred®, a program managed by the U.S. Department of Agriculture (USDA) to increase the use of bio-based products. BioPreferred® certification is an important distinction as consumers are increasingly focused on transparency and are more sceptical of “natural” claims in the marketplace. A BioPreferred® designation ensures consumers can trust the manufacturer’s bio-based content claims, as they are strictly monitored by the USDA.
Through their partnership, Green Biologics and Marianna are excited to bring this plant-derived acetone nail polish remover to others in the market, whether it be through private label or branded opportunities, to give consumers a product they can trust.

About Green Biologics
Green Biologics Ltd (GBL) is a renewable specialty chemicals company based in Abingdon, England with a wholly owned U.S. operating company, Green Biologics Inc., based in Little Falls, MN, with its sales and marketing headquarters in Medina, OH. GBL’s Clostridium fermentation platform converts a wide range of sustainable feedstocks into high performance green chemicals such as n-butanol, acetone, and through chemical synthesis, derivatives of n-butanol and acetone used by a growing global consumer and industrial products customer base in numerous markets including Coatings, Pharmaceuticals, Textiles and Cosmetics. The platform combines advanced high productivity fermentation with superior-performing proprietary Clostridium microbial biocatalysts and synthetic chemistry to produce a pipeline of high value green chemicals with optimal performance in downstream formulations.
With an aggressive product development pipeline and an intense focus on finding alternative superior performing proprietary opportunities, Green Biologics is transforming the global specialty chemicals market, providing its customers with products and technologies that are more sustainable and higher value than petroleum-based alternatives. For more information, visit www.greenbiologics.com.

About Marianna Industries
Marianna is a leading developer and manufacturer of innovative hair and beauty products for cosmetology schools, salon professionals, specialty retail and brand owners.

About Sally Beauty Supply LLC Sally Beauty Supply is a unit of Sally Beauty Holdings. Inc. (NYSE: SBH) an international specialty retailer and distributor of professional beauty supplies with revenues of approximately $3.9 billion annually. Through the Sally Beauty Supply and Beauty Systems Group businesses, the Company sells and distributes through 5,177 stores, including approximately 184 franchised units, and has operations throughout the United States, the United Kingdom, Belgium, Chile, Peru, Colombia, France, the Netherlands, Canada, Puerto Rico, Mexico, Ireland, Spain and Germany. Sally Beauty Supply stores offer up to 8,000 products for hair, skin, and nails through professional lines such as OPI®, China Glaze®, Wella®, Clairol®, Conair® and Hot Shot Tools®, as well as an extensive selection of proprietary merchandise. Beauty Systems Group stores, branded as CosmoProf or Armstrong McCall stores, along with its outside sales consultants, sell up to 10,500 professionally branded products including Paul Mitchell®, Wella®, Matrix®, Schwarzkopf®, Kenra®, Goldwell®, Joico® and Aquage®, intended for use in salons and for resale by salons to retail consumers. For more information about Sally Beauty Holdings, Inc., please visit sallybeautyholdings.com.

Contact Information
Green Biologics, Inc.
Attn: David Anderson
Global Vice President Marketing
david.anderson@greenbiologics.com
Website: www.greenbiologics.com

26/06/2018

• NodThera discovers and develops next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation

Cambridge, UK, 25 June 2018 – NodThera, a biotechnology company focused on the discovery and development of next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation, today announces it has closed its Series A financing round for a total of £28 million ($40 million). The Series A second closing was co-led by leading healthcare investors Sofinnova Partners and 5AM Ventures, with further participation from Epidarex Capital and F-Prime Capital Partners. NodThera was created and seed funded by life science investor, Epidarex Capital in 2016 based on earlier research conducted at Selvita, a Polish drug discovery company which remains a shareholder in NodThera. Henrijette Richter, PhD, Managing Partner of Sofinnova Partners and Scott Rocklage, PhD, Founding Partner of 5AM Ventures will both join the Board of Directors with Henrijette Richter additionally serving as Chair.

Alan Watt PhD MBA, Chief Scientific Officer and acting Chief Executive Officer, said: “Selective NLRP3 inflammasome inhibition represents one of the most exciting and promising approaches to treating diseases caused by chronic inflammation. We believe this approach has the potential to transform the treatment of patients suffering from these diseases where there are limited or no treatment options available. NodThera is committed to discovering and developing first-in-class molecules in our core disease areas, and working with the best partners in this space to address other chronic inflammation driven therapeutic areas. Together with our highly experienced management team, a strong scientific advisory board and the support of our international blue-chip investors, we are fully equipped to achieve our future goals.”

NodThera is developing small molecule inhibitors of the NLRP3 inflammasome, a multi-protein complex which initiates an innate immune response in the body. NodThera’s next generation approach could bring new treatment options to patients in areas where current standard of care is sub-optimal or non-existent across a wide range of therapeutic areas related to chronic inflammation. The NodThera strategy is to develop its leading drug candidate through to proof-of-concept in humans in an inflammatory disease and to bring forward further drug candidates specifically addressing high unmet medical needs such as neurodegenerative diseases and certain cancers. NodThera’s team combines a deep understanding of NLRP3 inflammasome inhibition with extensive pharmaceutical experience of drug discovery and development and is supported by a world-class team of scientific advisors.

Henrijette Richter PhD, Managing Partner, Sofinnova Partners and Chair of the Board of Directors said: “We are excited to invest in NodThera who we believe have the ability to address a wide range of disease areas related to chronic inflammation. We are pleased to have co-led this next chapter in NodThera’s development and look forward to supporting the management team as it establishes NodThera as a world-leader in NLRP3 inflammasome inhibition.”

Elizabeth Roper PhD, Partner, Epidarex Capital, said: “Since its inception, we saw the potential for NodThera to become a pioneer in the NLRP3 inflammasome space with the right approach to produce ground breaking products targeting multiple therapeutics areas. We are delighted to welcome such an experienced and international group of investors into the Company and believe this is strong validation of NodThera’s ambitions.”

For more information about NodThera please contact:
NodThera
Alan Watt, Chief Scientific Officer and acting Chief Executive Officer
Tel: +44 (0) 7717 801296
Email: alan.watt@nodthera.com

Consilium Strategic Communications
Amber Fennell, Ivar Milligan, Melissa Gardiner, Laura Thornton
Tel: +44 (0)20 3709 5700
Email: nodthera@consilium-comms.com

About NodThera
NodThera is a private biotechnology company focused on the discovery and development of next generation NLRP3 inflammasome inhibitors for the treatment of diseases driven by chronic inflammation. The Company is led by a strong management team that combines a deep understanding of NLRP3 inflammasome inhibition with extensive pharmaceutical experience of drug discovery and development. NodThera is building a pipeline of small molecule NLRP3 inhibitors through a highly differentiated, next generation approach that builds on and enhances existing understanding of NLRP3 biochemistry and its role in inflammation. The Company’s investors include Sofinnova Partners, 5AM Ventures, Epidarex Capital and F-Prime Capital Partners. Selvita, which spun the Company out of its immunology research platform in August 2016, remains a shareholder. For more information please visit: www.nodthera.com

About NLRP3 inhibitors
NLRP3-driven chronic inflammation is known to be the root cause of a wide range of debilitating diseases. Inflammasomes are multi-protein complexes that initiate an innate immune response in the body. Chronic inflammation can occur when inflammasomes are inappropriately activated by ‘danger’ signals in the body, leading to a number of diseases such as neurodegeneration, certain cancers, metabolic, cardiovascular and immune-inflammatory diseases. NLRP3 inflammasomes are uniquely activated by a wide range of these ‘danger’ signals, and specific inhibition of the NLRP3 inflammasome has the potential to treat the chronic inflammation that drives these diseases. Selective NLRP3 inhibitors offer safety advantages, as they leave the rest of the innate immune response intact to respond to infection. NLRP3 inhibitors can be made to target different tissues and organs thereby giving a broad disease application, and they can be taken orally providing a simple treatment regimen for patients.

About Epidarex Capital
Epidarex invests in early-stage, high growth life science and health technology companies in under-ventured markets in the US and Europe. With offices in Bethesda, Maryland and in Edinburgh, Scotland, Epidarex builds successful companies from world-class medical research to achieve commercial, patient-driven success.
Epidarex’s international management team has a track record of successfully partnering with scientists and entrepreneurs to develop highly innovative products for the global healthcare market. More information is available at www.epidarex.com

About Sofinnova Partners Sofinnova Partners is one of Europe’s leading venture capitalists specializing in life sciences. Based in Paris, the company invests in paradigm shift technologies alongside visionary entrepreneurs. Sofinnova Partners is primarily involved in start-ups and spin-offs of companies as a founding investor and leader. For more than 45 years, the company has supported more than 500 companies around the world that have become leaders in their market. Sofinnova Partners currently manages € 1.6 billion. For more information: www.sofinnova.fr

About 5AM Ventures
Founded in 2002, 5AM actively invests in next-generation life science companies. With ~$1 billion under management, 5AM has invested in 65 companies and successful exits which include Audentes Therapeutics (Nasdaq: BOLD), Cidara Therapeutics (Nasdaq: CDTX), DVS Sciences (acquired by Fluidigm), Envoy Therapeutics (acquired by Takeda), Flexion Therapeutics (Nasdaq: FLXN), Ikaria (acquired by Mallinckrodt), Ilypsa (acquired by Amgen), Incline Therapeutics (acquired by The Medicines Company), Marcadia Biotech (acquired by Roche), Novira Therapeutics (acquired by J&J), Pearl Therapeutics (acquired by AstraZeneca), Relypsa (Nasdaq: RLYP, acquired by Galenica), and scPharmaceuticals (Nasdaq: SCPH).

About F-Prime Capital Partners
F-Prime Capital Partners is a global venture capital firm investing in life sciences, healthcare, and technology. Since 1969, F-Prime has worked closely with entrepreneurs and academics to create innovative solutions to some of the world’s most significant challenges in healthcare and technology. For more information, please visit fprimecapital.com.

About Selvita
Selvita is one of the largest drug discovery companies in Europe. The company has two primary focus areas: research and development of breakthrough therapies in oncology and high quality, integrated drug discovery services. The company was established in 2007 and currently employs over 450 scientists.
Selvita is headquartered in Krakow, Poland, with a second research site in Poznan, Poland and international offices located in Cambridge, MA and San Francisco Bay Area, in the US, as well as in Cambridge, UK. Selvita is listed on the Warsaw Stock Exchange (WSE:SLV).

09/06/2018

Hookipa and Gilead will jointly develop therapeutics against HIV and Hepatitis B infections

  • Hookipa and Gilead will jointly research and Hookipa will manufacture arenavirus-based vectors for clinical development by Gilead
  • The deal expands the relationship between Hookipa and Gilead following Gilead’s participation in Hookipa’s Series C financing in December 2017
  • Total potential deal value exceeds $400 million, including upfront and milestone payments, plus research and development funding

Vienna, Austria and Foster City, CA, 5 June 2018 – Hookipa Biotech AG (“Hookipa”), a clinical-stage biotech company pioneering an innovative class of active immunization therapies for oncology and infectious diseases and Gilead Sciences, Inc., (“Gilead”), a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need, today announced that they have entered into a research collaboration and license agreement that grants Gilead exclusive rights to Hookipa’s TheraT® and Vaxwave® arenavirus vector-based immunization technologies for two major chronic infectious disease indications, hepatitis B virus (HBV) and human immunodeficiency virus (HIV).

Under the terms of the agreement, Gilead will provide an upfront payment of $10 million. Additionally, Hookipa will be eligible to receive milestone payments based upon the achievement of specified development, regulatory, and commercial milestones up to a total of more than $400 million. Gilead will fund all research and development activities. Hookipa will also be eligible to receive tiered royalties on net sales.

“Gilead, a world leader in innovative therapies against major viral diseases, is the ideal partner for us to drive our pipeline development in this area to the benefit of patients in need. This partnership is a strong recognition of our unique immunization technology, and helps us concentrate our own energy and resources on immuno-oncology,” commented Joern Aldag, Chief Executive Officer of Hookipa. “The collaborative HIV and HBV programs nicely complement our significant efforts in the infectious disease area with an exciting proprietary prophylactic CMV vaccine.”

“Gilead is committed to advancing innovative approaches directed at functional cures against HIV and HBV,” said Bill Lee, PhD, Executive Vice President of Research, Gilead. “We are convinced that Hookipa’s unique therapeutic vaccine technology, which has demonstrated excellent safety and immunogenicity in Phase 1 clinical studies, has strong potential to have synergistic effect with other Gilead cure efforts in both of these diseases areas. Our ultimate long-term goal is to eliminate the need for life-long antiviral therapy for millions of patients around the world.”

About Gilead Sciences, Inc.
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California.

About Hookipa Biotech
Hookipa Biotech is a clinical stage company developing next-generation immunotherapies for infectious diseases and cancer using novel proprietary arenavirus vector platforms.
Hookipa´s Vaxwave® technology presents a completely new replication-defective viral vector platform designed to overcome the limitations of current technologies. Vaxwave® is based on lymphocytic choriomeningitis virus (LCMV). In this vector the gene encoding the LCMV envelope protein, normally responsible for virus entry into target cells, has been deleted and replaced with an antigen of interest. The resulting vectors infect dendritic cells and stimulate very potent and long-lasting immune response, however they cannot replicate and are therefore non-pathogenic and inherently safe.
Hookipa’s TheraT® platform is based on an attenuated replicating arenavirus and is capable of eliciting the most potent T cell responses – a crucial step in treating patients with aggressive cancers. Significant pre-clinical data demonstrates that TheraT® is a powerful modality capable of turning “cold tumors hot” which should result in an additional layer of efficacy in the fight against solid tumors. Specifically, TheraT® has proven to be safe in animals as well as capable of eliciting uniquely potent antigen-specific CD8+ cytotoxic T cell responses and strong tumor control in mice. The first clinical trial with HB-201 targeting human papilloma virus-induced head and neck cancer is currently being prepared. This immuno-oncology technology is further being leveraged to target tumor self-antigens or shared neoantigens.
Find out more about Hookipa online at http://hookipabiotech.com/.

Gilead Forward-Looking Statements
This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors, including the risk that the parties may not realize the potential benefits of this collaboration, such as findings that are relevant to Gilead’s inflammatory diseases pipeline. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Annual Report on Form 10-K for the year ended December 31, 2017, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

Issued for and on behalf of Hookipa Biotech AG by Instinctif Partners. For further information please contact:
Hookipa
Joern Aldag Marine Popoff
CEO Communications Analyst
Hookipa Biotech AG Hookipa Biotech AG
jaldag@hookipabiotech.com mpopoff@hookipabiotech.com

Media enquiries
Sue Charles/ Ashley Tapp
Instinctif Partners
hookipa@instinctif.com
+44 (0)20 7866 7905
Gilead Investors Sung Lee, 650-524-7792 or Media Amy Flood, 650-522-5643

01/06/2018

Candidate to expand Zai Lab’s early-stage R&D programs, with an anticipated IND Filing for clinical studies in psoriasis in 2019

Shanghai, and Cambridge, UK, May 30, 2018 — Zai Lab Limited (NASDAQ: ZLAB), a Shanghai-based innovative biopharmaceutical company, and Crescendo Biologics Ltd (Crescendo Biologics), the developer of multi-functional biologics, announced today an exclusive, worldwide licensing agreement under which Zai Lab will develop, commercialize, and manufacture a topical, innovative antibody VH domain therapeutic for potential application in inflammatory indications. Crescendo Biologic’s product candidate was developed using Crescendo’s transgenic platform, which generates novel small, robust, and potent protein therapeutics based on fully human VH domain building blocks. Zai Lab anticipates filing an IND for this therapeutic candidate for clinical studies in psoriasis in 2019.
“Biologics-based therapies are increasingly effective in psoriasis and other skin conditions, but are often associated with treatment-limiting immunosuppressive side effects,” commented Harald Reinhart,
M.D., Chief Medical Officer, Autoimmune and Infectious Diseases at Zai Lab. “We see a clear benefit with topically administered dermatologic preparations which offers strong clinical efficacy and potentially safer for chronic administration.”

Peter Pack, CEO of Crescendo Biologics, commented, “We are pleased to sign this agreement with Zai Lab, a foremost developer of innovative medicines across diverse therapeutic areas where there are substantial unmet needs in global markets. We’re delighted with the pace and efficiency of Zai Lab’s plan to develop clinical proof of concept with our Humabody®. Crescendo Biologics is dedicated to advancing therapies with enhanced efficacy and improved safety profiles, and we believe there are significant synergies for our approach with the Zai Lab pipeline of autoimmune programs.”

Under the terms of the agreement, Crescendo Biologics has granted to Zai Lab a worldwide exclusive license to develop and commercialize its drug candidate for all indications. Zai Lab will be responsible for conducting all regulatory filings, clinical studies, and commercialization activities, with both companies participating in a Joint Development Committee. Zai Lab has made an upfront cash payment to Crescendo Biologics and will provide development, regulatory, and commercial milestones for multiple indications. Crescendo Biologics will also be eligible to receive tiered royalties on global sales.

About Crescendo Biologics
Crescendo Biologics is a biopharmaceutical company developing potent, truly differentiated Humabody® therapeutics in oncology with a proprietary pipeline focus on innovative targeted T-cell approaches.
At the heart of its proprietary pipeline, Crescendo Biologics has developed CB307, a novel bispecific PSMA-targeted T-cell engager for the selective activation of tumour-specific T-cells exclusively within the tumour microenvironment, thereby avoiding systemic toxicity. This highly modular format can be reconfigured to create a pipeline of multiple therapeutic candidates each treating a different cancer indication, by targeting any of a range of alternative tumour-specific markers. The Company’s ability to develop multi-functional Humabody® therapeutics is based on its unique, patent protected, transgenic mouse platform generating 100% human VH domain building blocks (Humabody® VH). These robust molecules can be configured to optimally engage therapeutic targets delivering novel biology and superior biodistribution. This results in larger therapeutic windows compared to conventional IgG-approaches.
Crescendo Biologics is pursuing novel Humabody®-based product opportunities, through in-house development and strategic partnerships, including multi-functional immuno-oncology modulators and Humabody® Drug Conjugates (HDCs), the next generation of ADCs. Humabody®-based formats can also be applied across a range of non-cancer indications.

Crescendo Biologics is located in Cambridge, UK, and is backed by blue-chip investors including Sofinnova Partners, IP Group, Takeda and Astellas.

For more information, please visit the website: www.crescendobiologics.com

About Zai Lab Zai Lab (NASDAQ:ZLAB) is a Shanghai-based innovative biopharmaceutical company focused on bringing transformative medicines for cancer, autoimmune and infectious diseases to patients in China and around the world. Zai Lab’s experienced team has secured partnerships with leading global biopharma companies, generating a broad pipeline of innovative drug candidates targeting the fast-growing segments of China’s pharmaceutical market and global unmet medical needs. Zai Lab’s vision is to become a fully integrated biopharmaceutical company, discovering, developing, manufacturing and commercializing its partners’ and its own products in order to impact human health worldwide. Zai Lab Forward-Looking Statements

This press release includes certain disclosures which contain “forward-looking statements,” including, without limitation, statements regarding the progress, clinical study timing and potential applications of its licens d Humabody® therapeutic candidate. You can identify forward-looking statements because they contain words such as “anticipate” and “expected.” Forward-looking statements are based on Zai Lab’s current expectations and assumptions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that may differ materially from those contemplated by the forward-looking statements, which are neither statements of historical fact nor guarantees or assurances of future performance. Important factors that could cause actual results to differ materially from those in the forward-looking statements are set forth in Zai Lab’s Annual Report on From 20-F for the fiscal year ended December 31, 2017, and its other filings with the Securities and Exchange Commission. Zai Lab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.

For more information, please contact: ZAI LAB

CONTACTS: Zai Lab Billy Cho +86 21 6163 7322 billy.cho@zailaboratory.com Media: Justin Jackson Burns McClellan, on behalf of Zai Lab 212-213-0006, ext. 327, jjackson@burnsmc.com Investors: Jill Steier Burns McClellan, on behalf of Zai Lab 212-213-0006, ext. 367, jsteier@burnsmc.com CRESCENDO BIOLOGICS CONTACTS: Dr Peter Pack, CEO + 44 (0)1223 497140 info@crescendobiologics.com For Media: Instinctif Partners for Crescendo Biologics Deborah Bell, Dr Christelle Kerouedan, Melanie Toyne-Sewell + 44 (0)20 7457 2020 crescendo@instinctif.com

22/05/2018

Sofinnova Partners significantly reinforces its team with an internationally renowned physician and entrepreneur

Paris, France – May 21st, 2018 — Sofinnova Partners, a leading European venture capital firm specialized in Life Sciences, has appointed Dr. Martin T. Rothman as Venture Partner. Dr. Rothman brings forty years of experience and a strong international network in the medical field to Sofinnova Partners.

As Venture Partner, Dr. Rothman will focus on helping the team identify and evaluate promising medical device companies and on mentoring entrepreneurs and physicians launching clinical innovations. Sofinnova Partners and Dr. Rothman have closely collaborated over many years. Dr. Rothman is the founder of LimFlow and an independent board member of HighLife, both portfolio companies of Sofinnova Partners. Until recently, he was Vice President of medical affairs for coronary, structural heart and renal denervation for Medtronic, based in Santa Rosa (CA), a position he held since 2010. He was involved in the development of the renal denervation program, the Trans-Aortic Valve Replacement program, and the Medtronic percutaneous mitral regurgitation program, including Twelve and the development of its Intrepid product and associated clinical strategy. Dr. Rothman previously practiced during 37 years in the U.K. as an interventional cardiologist, including 27 years at the London Chest Hospital (Barts and the London NHS Trust), where he has served for more than a decade as director of cardiac research and development. He is world renowned for his contributions to clinical research, training and education, and medical technology innovation in cardiovascular medicine. A regular presenter at medical meetings and author of peer-reviewed journal articles, Dr. Rothman has conducted many clinical trials related to interventional cardiology. As a true pioneer and leader in interventional cardiology, he has contributed to the development of numerous innovative medical technology for interventional cardiology.

Dr. Rothman also currently holds several positions in start-up companies in the cardiovascular field, some as a founder and based on his own inventions.

Dr. Martin T. Rothman says: “I am thrilled to join Sofinnova Partners’ team as Venture Partner. We share a common vision of entrepreneurship and a passion for bringing innovative therapies to patients and the medical community”.

Antoine Papiernik, Managing Partner and Chairman of Sofinnova Partners, adds: “Martin is an exceptional physician and repeat entrepreneur. His experience ideally complements our team and represents a key asset for Sofinnova Partners at a time when our activity is growing”.

Press contact for SOFINNOVA PARTNERS
Anne REIN
Tel: +33 6 03 35 92 05
@: anne.rein@strategiesimage.com